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Leuven, BelgiumBackground and Aims: Centralized endoscopic scoring may reduce variability, but evidence is lacking in pa-
tients with Crohn’s disease. We assessed the agreement of endoscopic scorings between site endoscopists and
one central reader by using data from the adalimumab Crohn’s disease clinical trial EXTEND.
Methods: Agreement between readers for Crohn’s Disease Endoscopic Index of Severity (CDEIS)–scored endos-
copies from 6 sites and Simple Endoscopic Score for Crohn’s Disease (SES-CD)–scored endoscopies from 19 sites
in EXTEND was evaluated at baseline and weeks 12 and 52. Agreement on total scores was calculated by using
intraclass correlation coefﬁcient (ICC). Kappa statistic or Spearman correlation coefﬁcient measured the agree-
ment between readers for each ileocolonic segment on CDEIS variables including deep ulceration, surface
involved, and ulcerated surface and SES-CD variables including ulcerated surface, size of ulcers, and affected
surface.
Results: ICCs on mean scores at baseline and weeks 12 and 52 were 0.78, 0.92, and 0.86 (CDEIS), and 0.77, 0.86,
and 0.82 (SES-CD), respectively. Site endoscopists consistently reported higher scores. High agreement was
observed for most segments and all time points for CDEIS variables and SES-CD large ulcers. Weak agreement
occurred for the right side of the colon at all time points for CDEIS deep ulceration and SES-CD large ulcers
and at baseline and week 12 for CDEIS ulcerated surface. Fair/moderate agreement occurred for SES-CD ulcerated
surface and moderate/high agreement for affected surface for all segments and time points.
Conclusions: Site and central readers showed high agreement on total CDEIS and SES-CD scores overall,
whereas variability for individual segments was observed. Weakest agreement occurred at baseline, with a greater
difference for SES-CD than for CDEIS score. (Clinical trial registration number: NCT00348283.) (Gastrointest En-
dosc 2016;83:188-97.)Crohn’s disease (CD) is characterized by chronic inﬂam-
mation leading to ulceration of the GI mucosa. Current
treatment goals for patients with CD include alleviating
symptoms and enabling a normal quality of life. Addition-ns: CD, Crohn’s disease; CDAI, Crohn’s Disease Activity In-
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Rutgeerts et al Comparison of site and central readings of endoscopy in Crohn’s diseaseto correlate well,4 achieving clinical and endoscopic
remission (termed deep remission5) is evolving as an
important target in the treatment of patients with CD.
Two measures of scoring endoscopic disease activity
have been partly validated for CD: the Crohn’s Disease
Endoscopic Index of Severity (CDEIS) and the Simple
Endoscopic Score for Crohn’s Disease (SES-CD).6,7 The
CDEIS is a scoring system in which 6 endoscopic variables
(presence of deep ulcers, superﬁcial ulcers, nonulcerated
stenosis, and ulcerated stenosis; proportion of ulcerated
surface and of surface involved by disease) are assessed
for each of the 5 ileocolonic segments: rectum, sigmoid
and left side of the colon, transverse colon, right side of
the colon, and ileum.6 CDEIS scores range from 0 to 44;
higher scores indicate more severe disease. The SES-CD is
a simpler scoring system based on 4 endoscopic variables
(presence and size of ulcers, proportion of surface covered
by ulcers, proportion of affected surface, and presence and
severity of stenosis), also measured for the 5 ileocolonic
segments.7 Each SES-CD variable is scored from 0 to 3,
with the sum of the scores for each variable ranging from
0 to 15 (except for the presence and extent of stenosis,
which ranges from 0-11), yielding a total SES-CD score of
0 to 56. As with the CDEIS, higher SES-CD scores indicate
more severe disease. CDEIS and SES-CD scores have been
shown to be reproducible and well-correlated.7,8 In
contrast, correlation between the Crohn’s Disease Activity
Index (CDAI) and CDEIS or the CDAI and SES-CD is poor.6,7
Although the CDEIS often is considered the standard for
evaluating endoscopic disease severity in CD, calculation of
the total score is complex, involving multiple measure-
ments, and therefore limits its widespread use. The SES-
CD score is easier to calculate and can be an alternative
to the CDEIS. Regardless of scoring method, endoscopic
assessment of disease activity can be subjective, and inter-
observer variation may ultimately inﬂuence clinical study
outcomes. The use of a centralized reviewer in clinical tri-
als has been shown to minimize variability, but the beneﬁt
of a centralized reviewer has mostly been observed in ul-
cerative colitis (UC) clinical trials.9-11 One study in patients
with UC demonstrated greater variability between site and
central readers at baseline (screening) than at posttreat-
ment endoscopy. The variability was shown not to be
random but rather a systematic upcoding of eligibility
scores by site readers compared with central readers, lead-
ing to a greater placebo response rate for patients with up-
coded scores.9 Data in patients with CD are lacking. In this
post hoc analysis, we determined the agreement between
the central and site readers of endoscopies by using data
from the CD clinical trial Extend the Safety and Efﬁcacy
of Adalimumab through Endoscopic Healing (EXTEND),1
which demonstrated that adalimumab was more effective
than placebo in inducing and maintaining mucosal healing.
It is important to note that a central review committee
in EXTEND assessed the primary endpoint of mucosal
healing at week 12. If the central reviewer disagreed withwww.giejournal.orga site’s assessment, an adjudication process was initiated,
involving up to two additional independent blinded re-
viewers. This post hoc analysis had a different objective,
which was to assess the agreement on the components
of CDEIS-scored and SES-CD–scored endoscopies between
site readers and a single blinded, central reviewer. The site
readers were physically on site and performed the readings
in real time; the blinded central reviewer in this analysis
evaluated all the recorded videos after trial completion.METHODS
EXTEND trial
Details of the EXTEND trial (NCT00348283) have been
published.1 Brieﬂy, EXTEND was a 52-week, double-
blind, placebo-controlled, randomized, maintenance/with-
drawal trial to assess the efﬁcacy of adalimumab on
mucosal healing in adult patients with moderately to
severely active CD, ileocolonic CD for 4 months, CDAI
score of 220 to 450, and mucosal ulceration documented
by recorded ileocolonoscopy at screening (performed at
study sites). Patients underwent up to 4 endoscopies
(screening, week 12, whenever moving to open-label
adalimumab after week 12, and week 2).Ileocolonoscopy scoring
For each ileocolonoscopy, 5 segments (ileum,
ascending [right side of the colon], transverse colon, de-
scending [left side of the colon and sigmoid colon], and
rectum) were recorded sequentially during endoscope
withdrawal. Each segment was recorded for 1 to 2 minutes
and was clearly separated. The minimal level of ileocolonic
inﬂammation for patient inclusion in the study was an SES-
CD ulcerated surface subscore 2 in 1 colon segment
(determined by study sites). The primary endpoint of the
EXTEND trial was the assessment of mucosal healing,
deﬁned as the absence of mucosal ulceration.
For this post hoc analysis, a single central reviewer un-
dertook all SES-CD and CDEIS scoring from videos for
comparison with scores from the study sites (Fig. 1).
Most study sites (13/19) did not correctly perform and
calculate the CDEIS score; however, this was mostly
because of incorrect completion of the case report form,
which allowed entry of the score as a decimal (correct)
or percentage (incorrect).Patients
Randomized patients who had ileocolonoscopies read
by both the blinded central reviewer and the site reader
(up to 2 designated endoscopists/site) were included in
this analysis. SES-CD scores from all 19 sites and CDEIS
scores from the 6 sites that performed and calculated the
CDEIS score correctly were used. To assess whether exclu-
sion of 13 sites would be likely to affect outcomes, SES-CDVolume 83, No. 1 : 2016 GASTROINTESTINAL ENDOSCOPY 189
Figure 1. Schematic of the current post hoc analysis assessing agreement between site and central readers in components of SES-CD–scored and CDEIS-
scored endoscopies. SES-CD, Simple Endoscopic Score for Crohn’s Disease; CDEIS, Crohn’s Disease Endoscopic Index of Severity.
Comparison of site and central readings of endoscopy in Crohn’s disease Rutgeerts et alscores also were calculated by using data from the 6 sites
that correctly entered the CDEIS values.Statistical analysis
Demographics were compared between patients with
and without CDEIS-scored endoscopies by using the Fisher
exact test for sex and race and 1-way analysis of variance for
continuous variables. Intraclass correlation coefﬁcients
(ICCs) that used a 2-way mixed model were calculated
to assess agreement between reviewers, as follows:
>0.74 Z excellent, 0.60 to 0.74 Z good, 0.40 to
0.59 Z fair, and <0.40 Z poor.12,13 Interobserver agree-
ment between the central and site reviewers of CDEIS
deep ulceration, SES-CD ulcerated surface (subscore 2),
SES-CD size of ulcers (subscore 2), SES-CD affected sur-
face (subscore 2), and reduction in total score (CDEIS
and SES-CD) from baseline was assessed by using the
kappa statistic (k), as follows: kZ 1, complete agreement;
k <1 to 0.81, almost perfect agreement; k Z 0.8 to 0.61,
high agreement; k Z 0.60 to 0.21, moderate/
fair agreement; k <0.2, low agreement; and k Z 0, no190 GASTROINTESTINAL ENDOSCOPY Volume 83, No. 1 : 2016correlation.14 The Spearman correlation coefﬁcient (r)
was used to measure the agreement between readers of
change in total score (CDEIS and SES-CD) from baseline,
CDEIS surface involved by the disease, and CDEIS ulcer-
ated surface, as follows: r Z 1, complete agreement;
r <1 to 0.90, very high agreement; r Z 0.89 to 0.70,
high agreement; r Z 0.69 to 0.30, moderate/fair agree-
ment; r <0.29, low/weak agreement; and r Z 0, no corre-
lation.15 When interobserver agreement in each segment
was scored, only patients with subscores in all segments
at the corresponding time point were included in the
analysis.RESULTS
Patients
Demographics and baseline characteristics of patients
randomized in EXTEND have been previously published.1
In the current analysis, patients were analyzed regardless
of randomized treatment; only patients who had
endoscopies read by both the central and site reviewerswww.giejournal.org
TABLE 1. Correlation between site and central readers on total CDEIS and SES-CD scores at each visit
CDEIS SES-CD SES-CD (6 sites)
Mean (SD)
central
reading
Mean (SD)
site
reading
ICC
(95% CI)
Mean (SD)
central
reading
Mean (SD)
site
reading
ICC
(95% CI)
Mean (SD)
central
reading
Mean (SD)
site
reading
ICC
(95% CI)
Baseline 11.6 (7.4)
N Z 52
12.9 (6.6)
N Z 52
0.78 (0.65-0.87) 12.6 (8.3)
N Z 129
16.8 (8.2)
N Z 129
0.77 (0.69-0.83) 14.2 (8.4)
N Z 52
17.4 (8.5)
N Z 52
0.86 (0.76-0.91)
Week
12
6.9 (6.6)
N Z 49
7.4 (6.8)
N Z 49
0.92 (0.86-0.95) 8.0 (7.4)
N Z 122
9.7 (8.1)
N Z 122
0.86 (0.81-0.90) 8.0 (7.0)
N Z 49
9.3 (8.1)
N Z 49
0.91 (0.85-0.95)
Week
52
4.9 (5.1)
N Z 34
5.6 (5.8)
N Z 34
0.86 (0.73-0.93) 6.2 (7.0)
N Z 84
8.1 (7.5)
N Z 84
0.82 (0.73-0.88) 6.4 (6.7)
N Z 34
7.4 (6.8)
N Z 34
0.83 (0.68-0.91)
CDEIS, Crohn’s Disease Endoscopic Index of Severity; SES-CD, Simple Endoscopic Score for Crohn’s Disease; SD, standard deviation; ICC, intraclass correlation coefficient based on
2-way mixed model; CI, confidence interval.
Figure 2. Correlation between central and site readings on mean change
from baseline in total CDEIS and SES-CD scores at weeks 12 and 52.
Spearman correlation coefﬁcient (r) at each time point is shown. BL, base-
line; CDEIS, Crohn’s Disease Endoscopic Index of Severity; SES-CD, Sim-
ple Endoscopic Score for Crohn’s Disease.
Rutgeerts et al Comparison of site and central readings of endoscopy in Crohn’s diseasewere included (Fig. 1). Because only 6 sites correctly
calculated the CDEIS score, CDEIS-scored endoscopies
were available for 52 patients at baseline, 49 at week 12,
and 34 at week 52. For SES-CD–scored endoscopies, data
from both the central and site reviewers were available
for all 129 randomized patients at baseline, 122 at week 12,
and 84 at week 52.Agreement on total scores
Mean CDEIS and SES-CD scores reported by central and
site readers and ICC coefﬁcients with 95% conﬁdence in-
tervals (CIs) are shown at baseline, week 12, and week
52 in Table 1. Excellent agreement (ICC >0.74) on total
CDEIS and SES-CD scores was observed between central
and site readers at all time points, especially after baseline.
Site readings were numerically higher than central readings
at all time points. When SES-CD data from only the 6 sites
that correctly performed and calculated CDEIS values were
used to compute SES-CD scores, similar ICC values were
obtained as for SES-CD scores from all of the sites.www.giejournal.orgHigh agreement was observed between readers when
change in total score (CDEIS or SES-CD) from baseline
was assessed at weeks 12 and 52 (Fig. 2). The strongest
agreement between readers in mean change from
baseline in total CDEIS score was observed at week 52
(r Z 0.86) and at weeks 12 and 52 for total SES-CD score
(r Z 0.73).
The interobserver agreement on the percentage reduc-
tion in total CDEIS score from baseline was stronger at
week 52 than at week 12 (Table 2). High agreement
between central and site readers occurred at week 52 in
assessing >25%, >50%, and >75% reduction in total
CDEIS score from baseline. At week 12, moderate or fair
to high agreement was observed, with the weakest
agreement in assessing >25% reduction in total CDEIS
score from baseline (kZ0.54). For SES-CD scores, agree-
ment between readers was moderate/fair to high at weeks
12 and 52. Agreement was strongest when assessing >75%
reduction in SES-CD score (kZ0.70) and weakest for
>25% reduction in total SES-CD score (kZ 0.53 at week 12;
kZ 0.59 at week 52).
Agreement in scoring different segments
CDEIS-scored endoscopies. High agreement was
observed between the central and site readers in most seg-
ments and time points when CDEIS deep ulceration was
scored (Table 3). Almost perfect agreement (0.8 <k <1)
was observed between readers of the rectum at baseline
and week 12, of the sigmoid/left side of the colon at all
time points, and in the ileum at baseline and week 52.
Perfect agreement (k Z 1) between readers occurred for
the transverse colon at week 12. Moderate and/or fair
agreement was observed in the right side of the colon at
all time points. Agreement between readers could not be
estimated for the rectum at week 52 because the site
reader rated all patients as having no deep ulcerations at
that time point.
High agreement between readers was observed when
CDEIS ulcerated surface in most segments and time points
was scored (Table 4). At week 52, agreement was very high
(0.9  r <1) in the ileum and complete (r Z 1) in theVolume 83, No. 1 : 2016 GASTROINTESTINAL ENDOSCOPY 191
TABLE 2. Degree of agreement (kappa values) between central and site assessments on reduction in total CDEIS and SES-CD scores from baseline
by visit
Week 12 Week 52
>25% Reduction >50% Reduction >75% Reduction >25% Reduction >50% Reduction >75% Reduction
CDEIS 0.54 0.62 0.64 0.71 0.80 0.75
SES-CD 0.53 0.64 0.70 0.59 0.67 0.70
CDEIS, Crohn’s Disease Endoscopic Index of Severity; SES-CD, Simple Endoscopic Score for Crohn’s Disease.
TABLE 3. Degree of agreement (kappa values) of CDEIS deep ulceration between site and central readings by segment and visit
Site reading
Central reading
Baseline N [ 43 Week 12 N [ 38 Week 52 N [ 29
No Yes k No Yes k No Yes k
Rectum
No 31 1 0.88 33 1 0.87 27 2 NE
Yes 1 10 0 4 0 0
Sigmoid and left side of colon
No 23 1 0.81 31 0 0.91 25 1 0.84
Yes 3 16 1 6 0 3
Transverse colon
No 31 3 0.74 34 0 1.0 25 1 0.63
Yes 1 8 0 4 1 2
Right side of colon
No 29 2 0.56 31 3 0.37 26 0 0.47
Yes 5 7 2 2 2 1
Ileum
No 16 1 0.90 23 4 0.77 19 1 0.92
Yes 1 25 0 11 0 9
CDEIS, Crohn’s Disease Endoscopic Index of Severity; NE, not estimable.
Comparison of site and central readings of endoscopy in Crohn’s disease Rutgeerts et altransverse colon. Agreement was high (0.70  r <0.89) in
the rectum at all time points. Moderate/fair agreement
between readers was observed in the sigmoid/left side of
the colon at week 52 and in the right side of the colon
at weeks 12 and 52. When CDEIS surface involved by the
disease was scored, high to very high agreement was
observed between readers in most segments and visits
(Supplementary Table 1, available online at www.
giejournal.org). Complete agreement was observed in the
transverse colon at week 52. Moderate/fair agreement
between readers was observed in the right side of the
colon at week 12 and in the rectum, sigmoid/left side of
the colon, and right side of the colon at week 52.
SES-CD–scored endoscopies. Moderate/fair agree-
ment was observed between readers in each segment and
at all time points when they scored SES-CD ulcerated surface
(subscore 2; Supplementary Table 2, available online
at www.giejournal.org). The agreement between readers
was strongest at week 12 in all segments except the
right side of the colon. When SES-CD size of ulcers192 GASTROINTESTINAL ENDOSCOPY Volume 83, No. 1 : 2016(subscore 2) was scored, a high degree of agreement
was observed between readers in most segments and time
points, except the right side of the colon, where moderate
agreement was observed at all time points (Table 5).
Moderate or fair agreement occurred between readers in
scoring SES-CD–affected surface (subscore 2) in all
segments and at all time points. The weakest agreement
between readers was observed in the right side of the
colon at baseline and in the ileum at baseline and week 12
(Table 6). Agreement on SES-CD presence of narrowing
(subscore 1) could not be estimated in most segments
over time because very few patients had baseline stenosis.CONCLUSIONS
This analysis evaluated the agreement between a central
reader and site endoscopists in scoring components of
CDEIS and SES-CD by using data from the EXTEND trial.
This was the ﬁrst study to emphasize central versus sitewww.giejournal.org
TABLE 4. Correlation between central and site readings of CDEIS ulcerated surface by segment and visit, Spearman correlation coefficient (r)
Baseline N [ 43 Week 12 N [ 38 Week 52 N [ 29
Mean (SD) r Mean (SD) r Mean (SD) r
Rectum
Central 0.67 (1.22) 0.83 0.47 (1.05) 0.85 0.19 (0.36) 0.76
Site 1.26 (2.00) 0.77 (1.90) 0.33 (0.72)
Sigmoid and left side of colon
Central 0.88 (1.16) 0.88 0.41 (0.87) 0.85 0.21 (0.60) 0.61
Site 1.75 (2.06) 0.74 (1.73) 0.58 (1.36)
Transverse colon
Central 0.52 (0.85) 0.88 0.37 (0.88) 0.85 0.17 (0.46) 1.00
Site 1.33 (2.02) 0.33 (0.84) 0.35 (0.86)
Right side of colon
Central 0.43 (0.69) 0.76 0.27 (0.47) 0.51 0.15 (0.46) 0.58
Site 1.30 (1.50) 0.44 (1.01) 0.44 (1.02)
Ileum
Central 1.17 (1.15) 0.73 0.69 (0.89) 0.88 0.54 (0.83) 0.91
Site 2.68 (2.67) 1.36 (1.97) 1.45 (1.89)
CDEIS, Crohn’s Disease Endoscopic Index of Severity.
Rutgeerts et al Comparison of site and central readings of endoscopy in Crohn’s diseasereading correlations for the scoring components of CDEIS
and SES-CD by using data from the EXTEND trial. Our re-
sults demonstrate that moderate to high agreement
occurred between the central and site readers in assessing
total endoscopic score and also in evaluating lesions in in-
dividual colon segments. Good agreement was observed
between readers regardless of scoring method used
(CDEIS, ICC 0.78-0.92; SES-CD, ICC 0.77-0.86).6 Although
high agreement between readers in total SES-CD score
was observed overall, weaker agreement occurred in
scoring SES-CD ulcerated surface in most ileocolonic seg-
ments, namely the sigmoid and left side of the colon, right
side of the colon, and ileum.
Differences in agreement between the central and site re-
viewers occurred mostly at study baseline, where site
readers reported higher CDEIS and SES-CD scores than
did the central reader. This result was not unexpected
because the site provided the initial SES-CD assessment.
Inﬂation in scoring by site readers also has been reported
for other CD and UC studies.3,9 It is important to note, how-
ever, that the difference in agreement observed at baseline
in this analysis is between the site reader and the one central
reader who assessed the endoscopy videos after the clinical
trial was completed and is not between the site readers and
the central review committee that assessed mucosal ulcera-
tion during the trial. Over time, the agreement between
readers strengthened, but site readers continued to report
higher total CDEIS and SES-CD scores than did the central
reader at weeks 12 and 52.
One possible explanation for the discrepancy between
readers in SES-CD–scored endoscopies may be that the cen-
tral reviewer was arbitrarily limited to 1-minute recordings ofwww.giejournal.orgeach ileocolonic segment prepared by the site endoscopist.
An important point to consider is that the central reviewer
determined the extent and degree of ulceration based
on the short recorded segments. Aphthous ulcers and
smaller extent of ulceration may be more difﬁcult to distin-
guish in a recorded video than when the endoscopy is per-
formed live and the reader has access to the entire colon
in real time. Although the possibility exists that the differ-
ence in site and central scoring is related to site readers
inﬂating scores to qualify patients into the trial, the pattern
of higher scoring by site readers also was observed at weeks
12 and 52,which argues against upcoding only at baseline for
trial eligibility. Rather, these data suggest that determining
disease extent and ulceration in real timemay bemore accu-
rate than assessing it from a recorded video segment. This is
especially apparent when the agreement between site and
central readers in SES-CD ulcerated surface and in certain
segments such as the right side of the colon is assessed,
where agreement between readers was quite poor. Howev-
er, both phenomena may be occurring because the magni-
tude of difference (ie, the magnitude of upcoding) was
greatest at baseline. It should be noted that, in this study, pa-
tients were not being re-randomized to maintenance ther-
apy at the primary endpoint (week 12) based on
endoscopic response. In contrast, in other study designs in
which patients are assessed at the end of an induction trial
and then re-randomized to maintenance therapy based on
the endoscopic response at the end of induction (yes/no),
as have been used in UC, there is a potential incentive for
site readers to upcode endoscopic scores so that the patient
is judged to not be a success and can then enter an open-
label treatment protocol. To be clear, response criteria forVolume 83, No. 1 : 2016 GASTROINTESTINAL ENDOSCOPY 193
TABLE 5. Degree of agreement (kappa values) of SES-CD large size of ulcers (subscore ≥2) between site and central readings by segment and
visit
Site reading
Central reading
Baseline N [ 103 Week 12 N [ 95 Week 52 N [ 71
No Yes k No Yes k No Yes k
Rectum
No 59 9 0.73 69 9 0.62 55 6 0.72
Yes 4 31 3 14 0 10
Sigmoid and left side of colon
No 49 6 0.75 67 8 0.71 53 7 0.65
Yes 7 41 2 18 1 10
Transverse colon
No 70 7 0.67 75 5 0.65 63 1 0.93
Yes 6 20 4 11 0 7
Right side of colon
No 68 8 0.51 77 8 0.43 62 2 0.46
Yes 11 16 4 6 4 3
Ileum
No 54 7 0.74 69 7 0.80 52 3 0.85
Yes 6 36 0 19 1 15
SES-CD, Simple Endoscopic Score for Crohn’s Disease.
Comparison of site and central readings of endoscopy in Crohn’s disease Rutgeerts et alendoscopic CD activity have not been validated. Thus, de-
pending on the study design, there is an incentive for site
readers to upcode at baseline and possibly at the end of in-
duction. When determining whether to use central readers
to qualify patients for a study and/or for determination of
the endoscopic endpoint, the risk of site-reader bias (inten-
tional upcoding) must be weighed against the potential ad-
vantages of the site reader directly observing the lesions in
real time. More data are needed to better understand these
two competing phenomena.
Although a high degree of agreement generally was
observed between the central and site readers when
they assessed different lesions in each segment, assess-
ment of the right side of the colon for CDEIS deep ulcer-
ation, CDEIS ulcerated surface, SES-CD size of ulcers,
and SES-CD ulcerated surface consistently showed weaker
agreement between readers at all 3 time points. Although
the right side of the colon may be difﬁcult to view with
endoscopy, this cannot completely explain the weak
agreement observed between readers because almost per-
fect agreement was observed in the right side of the colon
when CDEIS affected surface (at baseline, week 12,
and week 52) was assessed, and high agreement
was observed when SES-CD–affected surface (at weeks
12 and 52) was assessed. The reason for the weaker
agreement in the right side of the colon is of interest
and warrants further analysis.
The results of this study have important implications for
clinical trials that include endpoints assessing endoscopic
activity. The use of a central reader has been introduced194 GASTROINTESTINAL ENDOSCOPY Volume 83, No. 1 : 2016to reduce variability in interpretation of clinical trial results.
As stated earlier, this variability could inﬂuence the inter-
pretation of treatment efﬁcacy. However, we demonstrated
that endoscopies scored by site readers in EXTEND corre-
lated well overall with those scored by the central reader of
this study. The correlation between site and central readers
on total CDEIS and SES-CD scores observed here is similar
to the interrater agreement observed between 4 central
readers recently reported by Khanna et al.16 In the
Khanna study, kappa value for interobserver agreement
on the CDEIS score was 0.72 and SES-CD score was
0.84,16 whereas correlation between site and central
readers in this analysis ranged from 0.78 to 0.92 and 0.77
to 0.86 for total CDEIS and SES-CD scores, respectively.
There was high agreement between readers when >75%
reduction in total CDEIS score from baseline was assessed
at week 52. Thus, at later time points, our results suggest
that central readers and well-trained site readers are simi-
larly effective at scoring endoscopies (understanding the
limitation detailed above, that in the current study there
was no incentive for the site readers to upcode at the later
time points).
The CDEIS score was not reported correctly at 13 of
the 19 sites; however, this was mostly because of incor-
rect completion of the case report form, which allowed
entry of the score as a decimal (correct) or a percentage
(incorrect). Investigators that use the CDEIS should be
made aware of the correct data input format for CDEIS
scores, as prospectively deﬁned for the research being
conducted.www.giejournal.org
TABLE 6. Degree of agreement (kappa values) of SES-CD affected surface (subscore ≥2) between site and central readings by segment and visit
Site reading
Central reading
Baseline N [ 103 Week 12 N [ 95 Week 52 N [ 71
No Yes k No Yes k No Yes k
Rectum
No 62 3 0.65 66 2 0.66 58 3 0.57
Yes 13 25 10 17 4 6
Sigmoid and left side of colon
No 52 4 0.60 68 4 0.60 56 1 0.58
Yes 16 31 9 14 7 7
Transverse colon
No 65 3 0.55 73 0 0.61 61 0 0.72
Yes 16 19 11 11 4 6
Right side of colon
No 72 2 0.49 76 0 0.69 62 0 0.58
Yes 16 13 8 11 5 4
Ileum
No 60 6 0.48 77 7 0.49 60 4 0.75
Yes 17 20 4 7 0 7
SES-CD, Simple Endoscopic Score for Crohn’s Disease.
Rutgeerts et al Comparison of site and central readings of endoscopy in Crohn’s diseaseThese data also have important implications on the
management of patients with active disease. Allez et al17
demonstrated that the presence of deep ulcers in
patients with active ileocolonic CD is a signiﬁcant short-
term and long-term predictor for colectomy. Although a
limited number of sites were included in the CDEIS anal-
ysis, high agreement between site and central readers on
scoring CDEIS deep ulceration was observed at all 3 time
points. Thus, our results imply that endoscopists who are
experienced in calculating CDEIS can identify patients
with more severe disease, who may require more aggres-
sive therapy. For agreement on SES-CD ulcerated surface,
it is important to consider that the fair to moderate agree-
ment observed between readers may be inﬂuenced by the
systematic upgrading of scores by site readers or the limi-
tation of video recordings for the central reviewer, as dis-
cussed earlier.
A few limitations of this analysis exist. Fundamentally,
there is the inherent risk of bias found with any post hoc
analysis. Endoscopies that use CDEIS scoring were included
from only the 6 sites that performed CDEIS correctly,
whereas SES-CD–scored endoscopies were included from
all 19 sites in EXTEND. The small number of sites that re-
ported the CDEIS correctly may limit the ability to compare
the interobserver agreement between CDEIS and SES-CD
scores. As mentioned earlier, the stronger agreement
observed between reviewers who used CDEIS rather than
SES-CD scoring could be due to highly experienced and
trained site reviewers present at those 6 sites. However, a
subanalysis that used only the 6 sites that calculated CDEIS
correctly showed similar kappa values to those observedwww.giejournal.orgwhen data from all sites in EXTEND were included in most
segments (Supplementary Table 3, available online at
www.giejournal.org). Second, although a central review
committee with up to 3 central reviewers and up to 2
designated site readers evaluated endoscopy readings
in EXTEND, the endoscopy data included in this
analysis were rescored by the one blinded central reviewer
and were compared with the combined data of the site
reviewers. Thus, intraobserver agreement between readers
could not be measured here. Last, short video recordings
(1 minute) prepared by the site endoscopists could lead to
a biased scoring of the endoscopy by the central reader,
which may affect the degree of agreement observed
between site and central readers.
In conclusion, this study demonstrates that a high de-
gree of agreement occurred overall between site endo-
scopists and a blinded central reader who used data from
the EXTEND trial. However, the evidence of upgrading
endoscopic scores at baseline for site endoscopists relative
to the central reader resulted in weaker agreement at base-
line than at subsequent time points. There was important
variability in agreement by anatomic region and for the
presence of ulcers, suggesting that certain ileocolonic seg-
ments may be more difﬁcult to assess and require expert
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SUPPLEMENTARY TABLE 1. Correlation between central and site readings of CDEIS surface involved by the disease by segment and visit,
Spearman correlation coefficient (r)
Baseline N [ 43 Week 12 N [ 38 Week 52 N [ 29
Mean (SD) r Mean (SD) r Mean (SD) r
Rectum
Central 2.42 (3.56) 0.82 1.47 (3.10) 0.96 0.50 (1.05) 0.66
Site 2.81 (3.52) 1.87 (3.31) 0.66 (1.24)
Sigmoid and left side of colon
Central 3.18 (3.69) 0.93 1.45 (2.74) 0.87 0.58 (1.57) 0.55
Site 3.40 (3.55) 1.77 (2.86) 0.78 (1.76)
Transverse colon
Central 2.20 (3.57) 0.93 1.35 (3.06) 0.81 0.60 (1.89) 1.00
Site 2.33 (3.47) 1.31 (2.78) 0.53 (1.47)
Right side of colon
Central 1.76 (3.07) 0.88 1.33 (2.71) 0.65 0.51 (1.62) 0.45
Site 2.54 (3.38) 1.38 (2.83) 0.62 (1.69)
Ileum
Central 3.67 (3.64) 0.91 2.53 (3.46) 0.82 1.92 (2.84) 0.90
Site 4.52 (4.07) 2.51 (3.37) 2.33 (3.29)
CDEIS, Crohn’s Disease Endoscopic Index of Severity.
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SUPPLEMENTARY TABLE 2. Degree of agreement (kappa values) of SES-CD ulcerated surface (subscore ≥2) between site and central readings by
segment and visit
Site reading
Central reading
Baseline N [ 103 Week 12 N [ 95 Week 52 N [ 71
No Yes k No Yes k No Yes k
Rectum
No 67 1 0.59 76 1 0.59 59 2 0.53
Yes 16 19 9 9 5 5
Sigmoid and left side of colon
No 52 0 0.37 74 1 0.53 59 0 0.45
Yes 32 19 11 9 8 4
Transverse colon
No 74 0 0.43 82 0 0.60 63 0 0.37
Yes 19 10 7 6 6 2
Right side of colon
No 73 0 0.34 84 0 0.28 67 0 0.39
Yes 22 8 9 2 3 1
Ileum
No 51 1 0.28 76 1 0.59 55 1 0.47
Yes 36 15 9 9 9 6
SES-CD, Simple Endoscopic Score for Crohn’s Disease.
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SUPPLEMENTARY TABLE 3. Agreement (kappa values) on SES-CD components by segment and visit in all sites and the 6 sites that calculated
CDEIS correctly
Baseline N [ 43 Week 12 N [ 38 Week 52 N [ 29
Ulcerated
surface
Affected
surface
Size of
ulcers
Ulcerated
surface
Affected
surface
Size of
ulcers
Ulcerated
surface
Affected
surface
Size of
ulcers
Rectum
All sites 0.59 0.65 0.73 0.59 0.66 0.62 0.53 0.57 0.72
6 sites 0.64 0.61 0.72 0.84 0.61 0.69 0.65 NE 0.63
Sigmoid and left side of
colon
All sites 0.37 0.60 0.75 0.53 0.60 0.71 0.45 0.58 0.65
6 sites 0.52 0.69 0.86 0.72 0.68 1.0 0.47 0.46 0.71
Transverse colon
All sites 0.43 0.55 0.67 0.60 0.61 0.65 0.37 0.72 0.93
6 sites 0.42 0.81 0.77 0.84 0.63 0.87 0.47 1.0 1.0
Right side of colon
All sites 0.34 0.49 0.51 0.28 0.69 0.43 0.39 0.58 0.46
6 sites 0.46 0.78 0.58 NE 1.0 0.47 0.65 1.0 0.36
Ileum
All sites 0.28 0.48 0.74 0.59 0.49 0.80 0.47 0.75 0.85
6 sites 0.25 0.72 0.80 0.58 0.65 0.83 0.51 0.90 0.93
SES-CD, Simple Endoscopic Score for Crohn’s Disease; CDEIS, Crohn’s Disease Endoscopic Index of Severity; NE, not estimable.
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